Observational studyAIDS research and therapy2026
Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV-TR cohort.
Observational study in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhase 3 trials have established the long-term efficacy and safety of BIC/FTC/TAF for both treatment-naïve and treatment-experienced people with HIV (PWH). Real-world evidence in patients with very high baseline viral load remains limited.
methodsThis was a non-interventional, observational, retrospective analysis across 33 tertiary centers participating in the KLIMIK HIV-TR cohort. Adults (≥ 18 years) who initiated single-tablet BIC/FTC/TAF on or before August 31, 2022 were included. The primary endpoint was virological suppression at week-48, defined as HIV-1 RNA < 200 copies/mL. Suppression was further stratified by baseline viral load (< 100,000; > 100,000; > 1,000,000 copies/mL).
results2262 patients were analyzed (1122 treatment-naïve [49.6%], 1140 treatment-experienced [50.4%]). Among treatment-naïve patients, 88.5% had baseline HIV-1 RNA > 100,000 copies/mL and 24.2% > 1,000,000 copies/mL; 55.7% had CD4 < 350 cells/mm
conclusionsHigh virological suppression rates were observed among both treatment-naïve patients with very high baseline viral loads and treatment-experienced patients, supporting the effectiveness and safety profile of BIC/FTC/TAF in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.